• Home
  • About Us
    • Who we are
    • Our Early History
    • Technology
    • Target Markets
      • Venous and pressure ulcers
      • Other Applications
    • Business Model
    • Licensing
    • Clinical Trial
    • Publications & Presentations
    • Company Milestones
    • Focus
  • The Company
    • Board & Management
      • Paul Wright
      • Mark Richardson
      • George Baumanis
      • Stuart Usher
  • Advisory Team
    • Intellectual Property
      • Vaughan Barlow
      • Tom Boyce
      • Audrey Yap
      • Yvette Flanigan
    • Principal Advisor
      • Mark Woolley
    • Medical and Scientific Advisory Committee
      • James Fries
      • Michael Woodward
    • Scientific
      • Richard Lipscombe
    • Clinical
      • Geoffrey Mitchell
    • Health Economics
      • Nicholas Graves
  • Media
  • Links
  • Members Log in
  • Contact Us

News Headlines

> 18/01/10
Phoenix Eagle commences clinical trial.


> 01/12/09
OPAL A-1001 clinical trial has been approved by the Human Research Ethics Committee of the Austin Hospital.

The Phoenix Eagle Advisory Team

Principal Advisor - Mark Woolley

Principal Advisor - Mark Woolley

Mark Woolley, PhD, coordinates Phoenix Eagle’s scientific, clinical and regulatory projects, particularly in the areas of communications regarding clinical trial design and scientific study design and results. He has more than 20 years of experience in medical writing, clinical research and drug development. He is the Managing Director and co-founder with his wife of ProScribe Medical Communications. Before founding ProScribe, Mark was Clinical Research Manager at Bayer. As Clinical Research Manager, he was responsible for all clinical trials conducted in Australia, New Zealand and Asia.

The Phoenix Eagle Company Pty Ltd website is proudly maintained by NetBiz Enterprises.